Skip to main content
SpringerLink
Log in
Book cover

Clinical Ophthalmic Oncology pp 255–263Cite as

Non-ocular Tumors and Other Long-Term Complications

  • Chapter
  • First Online:

  • 486 Accesses

Abstract

In the United States and other developed nations, more patients with retinoblastoma will die from non-ocular second malignant neoplasms than from their primary intraocular tumor. There is an increased lifetime risk of the development of second malignant neoplasms in survivors of heritable retinoblastoma compared with their nonheritable counterparts. Radiation increases the risk of second malignant neoplasms and should be avoided when possible. All patients at risk must be educated to remain vigilant for future signs or symptoms of malignancies and counseled to avoid exposure to other mutagens. The prognosis for patients with second malignant neoplasms is guarded and underscores the importance of counseling patients with the heritable form of the disease.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Fidler MM, Reulen RC, Winter DL, et al. Risk of subsequent bone cancers among 69 460 five-year survivors of childhood and adolescent cancer in Europe. JNCI J Natl Cancer Inst. 2018;110(2):183–94.

    Article  Google Scholar 

  2. Bright CJ, Hawkins MM, Winter DL, et al. Risk of soft-tissue sarcoma among 69 460 five-year survivors of childhood cancer in Europe. JNCI J Natl Cancer Inst. 2018;110(6):649–60.

    Article  Google Scholar 

  3. Marees T, Moll AC, Imhoff SM, et al. Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up. J Natl Cancer Inst. 2008;100(24):1771–9.

    Article  Google Scholar 

  4. Kleinerman RA, Tucker MA, Tarone RE, et al. Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended study. J Clin Oncol. 2005;23(10):2722–9.

    Google Scholar 

  5. Jakobiec FA, Tso MO, Zimmerman LE, et al. Retinoblastoma and intracranial malignancy. Cancer. 1977;39(5):2048–58.

    Article  CAS  Google Scholar 

  6. Bader JL, Miller RW, Meadows AT, et al. Trilateral retinoblastoma. Lancet. 1980;2(8194):582–3.

    Article  CAS  Google Scholar 

  7. Kivela T. Trilateral retinoblastoma: a meta-analysis of hereditary retinoblastoma associated with primary ectopic intracranial retinoblastoma. J Clin Oncol. 1999;17(6):1829–37.

    Article  CAS  Google Scholar 

  8. Nathan PC, Daugherty CK, Wroblewski KE, et al. Family physician preferences and knowledge gaps regarding the care of adolescent and young adult survivors of childhood cancer. J Cancer Surviv. 2013;7(3):275–82.

    Article  Google Scholar 

  9. Cance WG, Brennan MF, Dudas ME, et al. Altered expression of the retinoblastoma gene product in human sarcomas. N Engl J Med. 1990;323:1457–62.

    Article  CAS  Google Scholar 

  10. Reissman PR, Simon MA, Lee WH, et al. Studies of the retinoblastoma gene in human sarcomas. Oncogene. 1989;4:839–43.

    Google Scholar 

  11. Stratton MR, Williams S, Fisher C, et al. Structural alteration of the RB1 gene in human soft tissue tumours. Br J Cancer. 1989;60:202–5.

    Article  CAS  Google Scholar 

  12. Horowitz JM, Park SH, Bogenmann E, et al. Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. Proc Natl Acad Sci U S A. 1990;87:2775–9.

    Article  CAS  Google Scholar 

  13. Varley JM, Armour J, Swallow JE, et al. The retinoblastoma gene is frequently altered leading to loss of expression in primary breast tumours. Oncogene. 1989;4:725–9.

    CAS  PubMed  Google Scholar 

  14. Venter DJ, Bevan KL, Ludwig RL, et al. Retinoblastoma gene deletions in human glioblastomas. Oncogene. 1991;6:445–8.

    CAS  PubMed  Google Scholar 

  15. Abramson DH, Frank CM. Second nonocular tumors in survivors of bilateral retinoblastoma. A possible age effect on radiation-related risk. Ophthalmology. 1998;105:573–80.

    Article  CAS  Google Scholar 

  16. Moll AC, Imhof SM, Schouten-Van Meeteren AY, et al. Second primary tumors in hereditary retinoblastoma: a register-based study, 1945–1997: is there an age effect on radiation-related risk? Ophthalmology. 2001;108(6):1109–14.

    Article  CAS  Google Scholar 

  17. Abramson DH. Second nonocular cancers in retinoblastoma: a unified hypothesis. The Franceschetti lecture. Ophthalmic Genet. 1999;99:193–204.

    Article  Google Scholar 

  18. Wong FL, Boice JD, Abramson DH, et al. Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA. 1997;278:1262–7.

    Article  CAS  Google Scholar 

  19. Sethi RV, Shih HA, Yeap BY, et al. Second nonocular tumors among survivors of retinoblastoma treated with contemporary photon and proton radiotherapy. Cancer. 2014;120:126–33.

    Article  Google Scholar 

  20. Fletcher O, Easton D, Anderson K, et al. Lifetime risks of common cancers among retinoblastoma survivors. J Natl Cancer Inst. 2004;96:357–63.

    Article  Google Scholar 

  21. Eng G, Li FP, Abramson DH, et al. Mortality from second tumors among long-term survivors of retinoblastoma. J Natl Cancer Inst. 1993;85:1121–8.

    Article  CAS  Google Scholar 

  22. Abramson DH. Retinoblastoma in the 20th century: past success and future challenges. The Weisenfeld lecture. Invest Ophthalmol Vis Sci. 2005;46:2684–91.

    Article  Google Scholar 

  23. Chauveinc L, Mosseri V, Quintana E, et al. Osteosarcoma following retinoblastoma: age at onset and latency period. Ophthalmic Genet. 2001;22:77–88.

    Article  CAS  Google Scholar 

  24. Mohney BG, Robertson DM, Schomberg PJ, et al. Second nonocular tumors in survivors of heritable retinoblastoma and prior radiation therapy. Am J Ophthalmol. 1998;126:269–77.

    Article  CAS  Google Scholar 

  25. Wong JR, Morton LM, Tucker MA, et al. Risk of subsequent malignant neoplasm in long-term hereditary retinoblastoma survivors after chemotherapy and radiotherapy. J Clin Oncol. 2014;32:3284–90.

    Article  Google Scholar 

  26. Pedersen-Bjergaard J, Andersen MT, Andersen MK. Genetic pathways in the pathogenesis of therapy related myelodysplasia and acute myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2007;2007:392–7.

    Article  Google Scholar 

  27. Gombos DS, Hungerford J, Ambrason DH, et al. Secondary acute myelogenous leukemia in patients with retinoblastoma: is chemotherapy a factor? Ophthalmology. 2007;114:1378–83.

    Article  Google Scholar 

  28. Rodriguez-Galindo C, Wilson MW, Haik BG, et al. Treatment of intraocular retinoblastoma with vincristine and carboplatin. J Clin Oncol. 2003;21:2019–25.

    Article  CAS  Google Scholar 

  29. Qaddoumi I, Billups CA, Tagen M, et al. Topotecan and vincristine combination is effective against bilateral intraocular retinoblastoma and has manageable toxicity. Cancer. 2012;118(22):5663–70.

    Article  CAS  Google Scholar 

  30. Brennan RC, Qaddoumi I, Shenghua M, et al. Ocular salvage and vision preservation using a topotecan-based regimen for advanced intraocular retinoblastoma. J Clin Oncol. 2017;35(1):72–7.

    Article  CAS  Google Scholar 

  31. Kleinerman RA, Yu CL, Little MP, et al. Variation of second cancer risk by family history of retinoblastoma among long-term survivors. J Clin Oncol. 2012;30:950–7.

    Article  Google Scholar 

  32. Yu C, Tucker MA, Abramson DH, et al. Cause-specific mortality in long-term survivors of retinoblastoma. J Natl Cancer Inst. 2009;101:581–91.

    Article  Google Scholar 

  33. Kleinerman RA, Tarone RE, Abramson DH, et al. Hereditary retinoblastoma and risk of lung cancer. J Natl Cancer Inst. 2000;92:2037–9.

    Article  CAS  Google Scholar 

  34. Harbour JW, Lai SL, Whang-Peng J, et al. Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science. 1988;241:353–7.

    Article  CAS  Google Scholar 

  35. Li FP, Abramson DH, Tarone RE, et al. Hereditary retinoblastoma, lipoma, and second primary cancers. J Natl Cancer Inst. 1997;89:83–4, 109

    Article  CAS  Google Scholar 

  36. Dunkel IJ, Gerald WL, Rosenfield NS, et al. Outcome of patients with a history of bilateral retinoblastoma treated for a second malignancy: the memorial Sloan-Kettering experience. Med Pediatr Oncol. 1998;30:59–62.

    Article  CAS  Google Scholar 

  37. Fontanesi J, Parham DM, Pratt C, et al. Second malignant neoplasms in children with retinoblastoma: the St. Jude Children’s Research Hospital experience. Ophthalmic Genet. 1996;16:105–8.

    Article  Google Scholar 

  38. Aerts I, Pacquement H, Doz F, et al. Outcome of second malignancies after retinoblastoma: a retrospective analysis of 25 patients treated at the Institut Curie. Eur J Cancer. 2004;40:1522–9.

    Article  Google Scholar 

  39. American Academy of Dermatology. Skin cancer. https://www.cancer.org/cancer/melanoma-skin-cancer.html. Accessed 4 July 2018.

  40. US Preventive Services Task Force. Behavioral counseling to prevent skin cancer: US Preventive Services Task Force recommendation statement. JAMA. 2018;319(11):1134–42.

    Article  Google Scholar 

  41. Foster MC, Kleinerman RA, Abramson DH, et al. Tobacco use in adult long-term survivors of retinoblastoma. Cancer Epidemiol Biomark Prev. 2006;15(8):1464–8.

    Article  CAS  Google Scholar 

  42. U.S. Preventive Services Task Force. Counseling and interventions to prevent tobacco use and tobacco-caused disease in adults and pregnant women: U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med. 2009;150(8):551–5.

    Article  Google Scholar 

  43. CureSearch Children’s Oncology Group: Long-term follow-up guidelines for survivors of childhood, adolescent, and young adult cancers. Version 4.0. http://www.survivorshipguidelines.org/pdf/ltfuguidelines.pdf.

  44. Friedman DN, Lis E, Sklar CA, et al. Whole-body magnetic resonance imaging (WB-MRI) as surveillance for subsequent malignancies in survivors of hereditary retinoblastoma: a pilot study. Pediatr Blood Cancer. 2014;61(8):1440–4.

    Article  Google Scholar 

  45. de Jong MC, Kors WA, de Graaf P. Trilateral retinoblastoma: a systematic review and meta-analysis. Lancet Oncol. 2014;15(10):1157–67.

    Article  Google Scholar 

  46. Abramson DH, Melson MR, Dunkel IJ, et al. Third (fourth and fifth) nonocular tumors in survivors of retinoblastoma. Ophthalmology. 2001;108(10):1868–76.

    Article  CAS  Google Scholar 

  47. Chodick G, Kleinerman RA, Stovall M, et al. Risk of cataract extraction among adult retinoblastoma survivors. Arch Ophthalmol. 2009;127(11):1500–4.

    Article  Google Scholar 

  48. Suesskind D, Schrader M, Foerster MH, et al. Cataract formation: a possible complication of intra-arterial chemotherapy for retinoblastoma. Eur J Ophthalmol. 2014;24(3):449–53.

    Article  Google Scholar 

  49. Honavar SG, Shields CL, Shields JA, et al. Intraocular surgery after treatment of retinoblastoma. Arch Ophthalmol. 2001;119(11):1613–21.

    Article  CAS  Google Scholar 

  50. Moshfeghi DM, Wilson MW, Grizzard S, et al. Intraocular surgery after treatment of germline retinoblastoma. Arch Ophthalmol. 2005;123:1008–12; Osman IM, Abouzeid H, Balmer A, et al. Modern cataract surgery for radiation-induced cataracts in retinoblastoma. Br J Ophthalmol. 2011;95(2):227–30.

    Google Scholar 

  51. Hoehn ME, Irshad F, Kerr NC, et al. Outcomes after cataract extraction in young children with radiation-induced cataract and retinoblastoma. J AAPOS. 2010;14(3):232–4.

    Article  Google Scholar 

  52. Kim HM, Lee BJ, Kim JH, et al. Outcomes of cataract surgery following treatment for retinoblastoma. Korean J Ophthalmol. 2017;31(1):52–7.

    Article  Google Scholar 

  53. Velasquez-Aguilar M, Matiz-Moreno H, Amato-Almanza M, et al. Outcomes and complications after phacoemulsification in retinoblastoma patients with cataract after radiation treatment. Arch Soc Esp Oftalmol. 2017;92(4):160–5.

    Article  CAS  Google Scholar 

  54. Payne JF, Hutchinson AK, Hubbard GB, et al. Outcomes of cataract surgery following radiation treatment for retinoblastoma. J AAPOS. 2009;13(5):454–8.

    Article  Google Scholar 

  55. Portellos M, Buckley EG. Cataract surgery and intraocular lens implantation in patients with retinoblastoma. Arch Ophthalmol. 1998;116(4):449–52.

    Article  CAS  Google Scholar 

  56. Brooks HL, Meyer D, Shields JA, et al. Removal of radiation-induced cataract in patients treated for retinoblastoma. Arch Ophthalmol. 1990;108(12):1701–8.

    Article  Google Scholar 

  57. Hoehn ME. Visual rehabilitation. In: Rodriguez-Galindo C, Wilson MW, editors. Retinoblastoma, Pediatric oncology. New York: Springer Science+Business Media, LLC; 2010. p. 127–32. Print.

    Google Scholar 

  58. Lueder GT, Goyal R. Visual function after laser hyperthermia and chemotherapy for macular retinoblastoma. Am J Ophthalmol. 1996;121:582–4.

    Article  CAS  Google Scholar 

  59. Watts P, Westall C, Colpa L, et al. Visual results in children treated for macular retinoblastoma. Eye. 2002;16:75–80.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hamilton Eye Institute, Department of Ophthalmology, University of Tennessee Health Sciences Center, Memphis, TN, USA

    Benjamin C. King

  2. Department of Ophthalmology, University of Miami Bascom Palmer Eye Institute, Miami, FL, USA

    Brian C. Tse

  3. Department of Oncology, St. Jude Children’s Research Hospital, Memphis, TN, USA

    Rachel C. Brennan

  4. Hamilton Eye Institute, Department of Ophthalmology, Univserity of Tennessee Health Sciences Center, Memphis, TN, USA

    Matthew W. Wilson

Authors
  1. Benjamin C. King
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Brian C. Tse
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rachel C. Brennan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Matthew W. Wilson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matthew W. Wilson .

Editor information

Editors and Affiliations

  1. Associate Professor of Ophthalmology, Children’s Hospital Los Angeles, The USC Roski Eye Institute Keck School of Medicine, Los Angeles, CA, USA

    Jesse L. Berry

  2. Children’s Hospital Los Angeles, The USC Roski Eye Institute, Keck School of Medicine, Los Angeles, CA, USA

    Jonathan W. Kim

  3. University of Oxford, Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, UK

    Bertil E. Damato

  4. Department of Ophthalmic Oncology, Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA

    Arun D. Singh

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

King, B.C., Tse, B.C., Brennan, R.C., Wilson, M.W. (2019). Non-ocular Tumors and Other Long-Term Complications. In: Berry, J., Kim, J., Damato, B., Singh, A. (eds) Clinical Ophthalmic Oncology. Springer, Cham. https://doi.org/10.1007/978-3-030-11123-6_22

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-11123-6_22

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-11122-9

  • Online ISBN: 978-3-030-11123-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation